Published in Proc Natl Acad Sci U S A on October 03, 2012
Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer (2013) 1.23
Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol (2014) 1.19
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev (2015) 1.11
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol (2016) 1.03
Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene (2013) 0.94
Progress in the management of limited-stage small cell lung cancer. Cancer (2013) 0.93
Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer. Nucleic Acids Res (2014) 0.91
Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway. Cell Death Dis (2013) 0.90
Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis (2015) 0.89
Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Syst Biol (2013) 0.89
The kinome 'at large' in cancer. Nat Rev Cancer (2016) 0.88
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw (2014) 0.86
Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics (2014) 0.84
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget (2015) 0.83
Systems biology approaches to develop innovative strategies for lung cancer therapy. Cell Death Dis (2014) 0.81
Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin Lung Cancer (2014) 0.81
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer. Front Oncol (2015) 0.81
Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer. PLoS One (2014) 0.80
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget (2016) 0.80
Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res (2016) 0.79
Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. Mol Cancer Ther (2016) 0.78
Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res (2016) 0.77
[Molecular pathology of lung cancer. State of the art 2014]. Pathologe (2014) 0.76
Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma. World J Gastroenterol (2016) 0.75
The MYCN Protein in Health and Disease. Genes (Basel) (2017) 0.75
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell (2016) 0.75
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther (2016) 0.75
SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun (2017) 0.75
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS One (2017) 0.75
Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer (2017) 0.75
Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
The cellular geography of aurora kinases. Nat Rev Mol Cell Biol (2003) 6.40
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell (2009) 3.92
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell (2011) 2.63
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature (2012) 1.88
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem (2007) 1.81
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45
myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest (1987) 1.43
VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle (2007) 1.41
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem (2009) 1.21
Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products. Nat Chem (2010) 1.19
A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol (2009) 1.16
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood (2011) 1.11
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther (2012) 1.04
Identification of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase B. Angew Chem Int Ed Engl (2010) 1.01
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice. Cancer Res (1991) 0.91
Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorg Med Chem (2010) 0.79
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science (2005) 5.99
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Switching on and off fear by distinct neuronal circuits. Nature (2008) 5.22
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature (2013) 5.04
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Encoding of conditioned fear in central amygdala inhibitory circuits. Nature (2010) 4.29
Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest (2007) 4.21
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med (2006) 4.15
A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol (2009) 3.44
Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol Cell (2009) 3.38
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Retracted Cytohesins are cytoplasmic ErbB receptor activators. Cell (2010) 2.74
The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell (2010) 2.72
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
A multiplex assay with 52 single nucleotide polymorphisms for human identification. Electrophoresis (2006) 2.59
Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology (2003) 2.56
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg (2002) 2.46
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol (2010) 2.39
Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat Chem Biol (2010) 2.37
Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat Genet (2013) 2.36
Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc Natl Acad Sci U S A (2005) 2.35
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn (2007) 2.35
Validating Aurora B as an anti-cancer drug target. J Cell Sci (2006) 2.30
A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol (2009) 2.29
Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet (2003) 2.27
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. Dtsch Arztebl Int (2013) 2.09
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06
The scaffold tree--visualization of the scaffold universe by hierarchical scaffold classification. J Chem Inf Model (2007) 2.04
From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed Engl (2002) 2.03
Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat Chem Biol (2011) 2.00
DNA-based prediction of human externally visible characteristics in forensics: motivations, scientific challenges, and ethical considerations. Forensic Sci Int Genet (2009) 1.98